Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

and atopic dermatitis, providing physicians and their patients multiple forms of ZORYVE cream and ZORYVE foam to address ...

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Podiatrists and dermatologists explain the benefits of applying a foot cream. Here, shop the 12 best foot creams for dry feet ...

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

Atopic dermatitis, also known as atopic eczema, is a chronic inflammatory familial disease of the skin. It is characterized by an increased ability to form immunoglobulin E and a tendency to ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...